US HB2113 | 2017-2018 | 115th Congress
Status
Spectrum: Slight Partisan Bill (Republican 2-1)
Status: Introduced on April 20 2017 - 25% progression, died in committee
Action: 2017-04-21 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on April 20 2017 - 25% progression, died in committee
Action: 2017-04-21 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Speeding Access to Already Approved Pharmaceuticals Act of 2017 This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration to facilitate the development and expedite the review of a new drug, biological product, or medical device that has been approved in the European Union.
Title
Speeding Access to Already Approved Pharmaceuticals Act of 2017
Sponsors
Rep. Steve Stivers [R-OH] | Rep. Tim Ryan [D-OH] | Rep. Don Bacon [R-NE] |
History
Date | Chamber | Action |
---|---|---|
2017-04-21 | House | Referred to the Subcommittee on Health. |
2017-04-20 | House | Referred to the House Committee on Energy and Commerce. |
2017-04-20 | House | Introduced in House |
Subjects
Administrative law and regulatory procedures
Department of Health and Human Services
Drug safety, medical device, and laboratory regulation
Europe
European Union
Food and Drug Administration (FDA)
Health
Prescription drugs
Department of Health and Human Services
Drug safety, medical device, and laboratory regulation
Europe
European Union
Food and Drug Administration (FDA)
Health
Prescription drugs
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/115th-congress/house-bill/2113/all-info |
Text | https://www.congress.gov/115/bills/hr2113/BILLS-115hr2113ih.pdf |